40 results
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company N.V.
9 Aug 24
Other Events
5:23pm
, it will be in compliance with all applicable corporate governance requirements set forth in the Nasdaq’s listing rules that are then in effect.
(p) Non
424B5
NAMS
NewAmsterdam Pharma Company N.V.
9 Aug 24
Prospectus supplement for primary offering
5:21pm
included in the agenda.
In accordance with the Dutch Corporate Governance Code (the “DCGC”), shareholders who have the right to put an item … for the composition of the Board of Directors, with the assistance of our nomination and corporate governance committee. The Board of Directors will make any
S-3
NAMS
NewAmsterdam Pharma Company N.V.
3 Jul 24
Shelf registration
4:31pm
be adopted on items other than those that have been included in the agenda.
In accordance with the Dutch Corporate Governance Code (the “DCGC … governance committee. The Board of Directors will make any nomination for the appointment of a director with due regard to the rules and principles set forth
DEF 14A
NAMS
NewAmsterdam Pharma Company N.V.
9 May 24
Definitive proxy
4:15pm
Awards at 2023 Fiscal Year-End
DIRECTOR COMPENSATION
Director Compensation Table
CORPORATE GOVERNANCE
Board Structure
Independence of the Board … Management and Oversight
Shareholder Dialogue with the Company
Code of Business Conduct and Ethics
Corporate Governance Documents
Compensation
10-Q
2fjmkni5kxzt5vfnu364
8 May 24
Quarterly report
4:30pm
PRE 14A
sw6k7gui1k2mpkz
29 Apr 24
Preliminary proxy
5:00pm
POS AM
m6lc1
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
424B3
4t2q0b3bbceuhbto79b
12 Mar 24
Prospectus supplement
4:18pm
POS AM
gomyi9vc5
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
10-K
25pic1qxqe
28 Feb 24
Annual report
8:00am
10-K
EX-4.4
dqxgg5
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
9ylw41d2 212pnabg
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
eky9l877h0a7
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
p4agg eg4bq
13 Feb 24
Prospectus supplement for primary offering
5:19pm
F-3
EX-1.2
ao0cxj6 8vuhgk
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
4m8rp0
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
c9yu3d361gf1gkoq7
15 Aug 23
Prospectus supplement
4:52pm
POS AM
1a6qpoeve
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
83ig9lq2
7 Aug 23
Research and development expenses
7:24am